tbuckley/cabot-search huggingface dataset:
Dicentric Ph1 Chromosome
Authors: Jacqueline Whang-Peng, Turid A. Knutsen, Elaine C. Lee
Journal: JNCI Journal of the National Cancer Institute (1973)

Five cases in our chronic myelogenous leukemia series were originally categorized as Ph1-positive and later developed another variant of the Ph1 chromosome. With the new Giemsa banding technique, it appeared to be a dicentric Ph I chromosome. This chromosome was first noted 23 months after diagnosis, with the latest appearance at 57 months. Survival in 3 of the 5 patients after the appearance of the dicentric Ph1 chromosome was 6, 16, and 35 months; the other 2 are still alive.
Major Allergen Content of SQ-House Dust Mite Slit-Tablets Is Consistent and in Concordance with Patient Sensitivity Profiles in North America and Europe
Authors: Hendrik Nolte, Greg A. Plunkett, Mirko Bollen, Karin Grosch, Jorgen Nedergaard Larsen, Kaare Lund
Journal: Journal of Allergy and Clinical Immunology (2016)
Judge might reopen GSK paroxetine case
Authors: Clare Dyer
Journal: BMJ (2016)

A High Court compensation claim against the pharmaceutical company GlaxoSmithKline (GSK) over its antidepressant paroxetine may be revived, five years after the withdrawal of legal aid funding put it on hold shortly before the trial was due to start on 1 February 2011.

At the High Court in London, Mr Justice Foskett refused GSK an order to bring the case to a permanent halt.

The 103 claimants, whose new solicitors, Fortitude Law, had arranged commercial litigation funding, said …
Exploratory analysis of EGFR FISH criteria in Japanese non-small cell lung cancer patients treated with gefitinib
Authors: K. Kazuo, L. E. Morrison, H. Kimura, T. Sone, T. Araya, S. Tamori, Y. Tanbo, M. Fujimura, G. Speake, B. R. Holloway
Journal: Journal of Clinical Oncology (2007)

7599 Background: In the phase III Iressa (gefitinib) Survival Evaluation in Lung cancer (ISEL) trial, high epidermal growth factor receptor (EGFR) gene copy number was a predictor of a gefitinib effect on survival in patients (pts) with refractory advanced non-small-cell lung cancer (NSCLC) (hazard ratio 0.61 vs 1.16 for high vs low copy number; p=0.045) [JCO 2006;24:5034–42]. Although EGFR mutation status may predict response to gefitinib in Japanese pts, there is insufficient data to clarify if high EGFR gene copy number assessed by fluorescence in situ hybridization (FISH) is predictive in these pts. This analysis investigated the applicability of both published Colorado FISH criteria (Colorado Univ) and new FISH criteria to Japanese NSCLC pts. Methods: 58 tumor specimens from gefitinib-treated Japanese pts were analyzed using Vysis LSI EGFR and CEP7 (chromosome 7 control) FISH probes. Specimens were classed as FISH+ or - using Colorado and exploratory (EGFR/cell; CEP7/cell; EGFR/CEP7; % of cells with various numbers of EGFR or CEP7 signals) criteria. Results: Of the 58 pts, 17 (29%) had an objective response (OR). Using Colorado criteria, OR was 50% in the 14 FISH+ pts vs 23% in the 44 FISH- pts (2-sided Fisher's exact test p=0.089). There was a trend for an association between FISH+ status and improved survival (log rank p=0.15). Defining FISH+ as specimens with =5% cells containing &gt;5 EGFR signals, OR was significantly better among FISH+ pts vs FISH- pts (p=0.0030; 52% of the 23 FISH+ pts responding vs 14% of the 35 FISH- pts). A survival advantage was not indicated. Defining FISH+ as =74% of cells with EGFR or CEP7 loss (&lt;2 signals) or gain (&gt;2 signals), OR was significantly better among FISH+ pts vs FISH- pts (p=0.043; 45% of the 22 FISH+ pts responding vs 19% of the 36 FISH- pts). Association with survival had marginal significance (log rank p=0.061). Conclusions: These preliminary data have identified loss or gain of EGFR and CEP7 abnormality as promising biomarkers for response to gefitinib in Japanese NSCLC patients. Analysis of these markers for correlation with time to progression is ongoing. Investigation of these potential markers in other cohorts of patients is worthy of further evaluation. [Table: see text]
Brief Communication: Oncorna-Like Viruses in Baboon Prostate Tissue23
Authors: S. S. Kalter, S. A. Shain, G. C. Smith, B. McCullough, R. L. Heberling, A. J. Dalton
Journal: JNCI Journal of the National Cancer Institute (1975)

Oncorna-like virus particles were observed in prostate tissue of 2 of 11 baboons inoculated 3 years previously with a chemical carcinogen. There were no indications, however, of any relationship between the carcinogen and the development of virus particles. Biopsy specimens from the animals showed no evidence of neoplasia, and electron microscopic examination suggested that this virus should be categorized as a B-type oncornavirus.
Comment on Jakubowicz et al. Fasting Until Noon Triggers Increased Postprandial Hyperglycemia and Impaired Insulin Response After Lunch and Dinner in Individuals With Type 2 Diabetes: A Randomized Clinical Trial. Diabetes Care 2015;38:1820–1826
Authors: Om P. Ganda
Journal: Diabetes Care (2016)

More than 100 years ago, it was shown that oral ingestion of two successive carbohydrate meals results in an improved glucose tolerance in healthy people, a phenomenon known as the “Staub-Traugott” effect. In 1970, Metz and Friedenberg (1) reported that an improvement in glucose tolerance to sequential intravenous glucose loads could be seen in both subjects with normal glucose tolerance and with glucose intolerance after a second or even a third isocaloric glucose load. Much work was subsequently carried out to study the metabolic …
BRCA1-Down-Regulation In Chronic Myeloid Leukemia (CML) Occurs Via The Deubiquitinase / Tumor Suppressor BRCA1-Associated Protein 1 (BAP1)
Authors: Fatima Dkhissi, Djamel Aggoune, Julien Pontis, Marie Laure Bonnet, Marie Claude Meunier, Nathalie Sorel, Clémentine Bouneau, Annelise Bennaceur-Griscelli, François Guilhot, Jean-Claude Chomel, Slimane Ait-Si-Ali, Ali G Turhan
Journal: Blood (2013)
Abstract 17437: Transgenic Mice Overexpressing the ID Protein Myozap Are Sensitized to Pressure Overload and Develop a Progressive Protein-aggregate Associated Cardiomyopathy
Authors: Derk Frank, Reza Poyanmehr, Ashraf Y Rangrez, Thalia S Seeger, Christian Kuhn, Christine Grund, Werner W Franke, Norbert Frey
Journal: Circulation (2013)

The intercalated disc (ID) is an important component of the cell contact structures of cardiomyocytes establishing electro-mechanical coupling. In recent work, we could describe Myozap, a novel ID ...
Prognostic value of microRNAs (miRNAs) profiling in early-stage squamous cell lung cancer (SqCLC)
Authors: M. T. Skrzypski, A. Szymanowska, E. Jassem, R. Rzepko, R. Pawlowski, L. Wyrwicz, K. Goryca, T. Marjanski, W. Rzyman, J. Jassem
Journal: Journal of Clinical Oncology (2009)

7594 Background: About 50% of NSCLC patients (pts) will develop distant metastases following pulmonary resection. Currently, apart from clinical stage at diagnosis, there are no reliable clinical factors to select high risk pts for adjuvant chemotherapy. miRNAs profiling is expected to indicate pts with aggressive disease and to provide prognostic information. Confounding effect of NSCLC pathology heterogeneity justifies searching for prognostic miRNAs separately in SqCLC and adenocarcinoma. Methods: Fresh frozen tumor tissue was obtained from 30 SqCLC stage I-II pts during curative pulmonary resection. Of those, 15 pts developed distant metastases and 15 had no relapse after a median follow-up of 5.4 years (range, 3.1–6.9 years). RNA was isolated from tumor sections containing ≥60% of tumor cells per section. Expression of 380 miRNAs was analyzed by RT-PCR arrays (TLDAs-Appliedbiosystems). Raw data were normalized vs. the expression of U6 RNA and calibrated by ΔΔCt method. Results: Expression of 300 miRNAs was detected in tumor tissues. Expression of three miRNAs (193a[5p], 146b[5p] and 10b) differed between groups with and without metastases (t-Student test, p&lt;0.05). Due to the limited number of samples, proportional hazard regression for survival (Cox analysis) could not be performed on the full data set of 300 variables. Cox analysis performed for the top 5 miRNA identified with t-Student test showed significant correlation for 10b (p&lt;0.02). The internal consistency of data sets was tested using PCA, and three samples were excluded. In this modified test set, the top 10 miRNAs (ranked according to p-value of t test) revealed two significantly correlated miRNAs in Cox analysis: 484 and 146b (5p). Similar results were obtained for miRNAs expression defined as continuous or categorized variables. Conclusions: Four miRNAs: 10b, 146b, 193a(5p) and 484 are potentially related to high metastatic propensity of early stage SqCLC. Further validation is necessary to confirm their prognostic relevance in this tumor. No significant financial relationships to disclose.
Clinical pharmacodynamics of continuous infusion teniposide: systemic exposure as a determinant of response in a phase I trial.
Authors: J H Rodman, M Abromowitch, J A Sinkule, F A Hayes, G K Rivera, W E Evans
Journal: Journal of Clinical Oncology (1987)

Teniposide (VM-26) is an effective anticancer drug usually administered as a short infusion in doses of 150 to 165 mg/m2. The objectives of the trial reported here were to evaluate clinical responses and assess pharmacokinetic parameters as a determinant of outcome when VM-26 was administered as a 72-hour continuous infusion (CI) with doses escalated from 300 to 750 mg/m2 per course. Twenty-eight patients with recurrent leukemia, lymphoma, or neuroblastoma received 53 courses of CI VM-26 and 16 had measurable responses. There were two partial remissions and one stable disease among seven neuroblastoma patients and 13 of 21 leukemia/lymphoma patients had oncolytic responses (greater than or equal to 75% decrease in circulating blasts). Toxicity included moderate to severe mucositis and myelosuppression. Pharmacokinetic parameters determined during 35 courses administered to 23 patients were highly variable. Clearance (CI) ranged between 3.7 and 43.8 ml/min/m2, resulting in VM-26 plasma concentrations from 2.8 to 30.6 mg/L across all dose levels. The interpatient pharmacokinetic variability reflected in CI and VM-26 steady state concentrations (Css), obscured any dose-response relationship. However, when pharmacokinetic parameters for responding and nonresponding patients were compared, statistically significant relationships were observed. For responders, the mean Css was 15.2 mg/L and mean CI was 12.1 mL/min/m2; for nonresponders, mean Css was 6.2 mg/L (P less than .01) and mean CI was 21.3 mL/min/m2 (P less than .05). Thus, patients with higher CI and lower Css were less likely to respond. Clinical responses occurred in ten of ten patients with Css greater than 12 mg/L, and only five of 13 patients with Css less than 12 mg/L (P less than .01). In this study, interpatient pharmacokinetic variability yielded a four- to sixfold difference in intensity of systemic exposure (Css) within the same dose level, which was an important determinant of clinical response. These data indicate that achieving a VM-26 target concentration for individual patients could ensure an increased intensity of systemic exposure in patients with a high CI and improve the likelihood of effective therapy.
Effect of intravenous calcium and magnesium (IV CaMg) on oxaliplatin-induced sensory neurotoxicity (sNT) in adjuvant colon cancer: Results of the phase III placebo-controlled, double-blind NCCTG trial N04C7
Authors: D. A. Nikcevich, A. Grothey, J. A. Sloan, J. W. Kugler, P. T. Silberstein, T. Dentchev, D. B. Wender, P. J. Novotny, H. E. Windschitl, C. L. Loprinzi
Journal: Journal of Clinical Oncology (2008)

4009 Background: Cumulative sNT is the dose-limiting toxicity of oxaliplatin which commonly leads to early discontinuation of oxaliplatin-based therapy in the palliative and adjuvant setting. In a retrospective, non-randomized study, CaMg was associated with reduced oxaliplatin-induced sNT (Gamelin, 2004). N04C7 prospectively evaluated the activity of IV CaMg as a neuroprotectant against cumulative oxaliplatin-related sNT. Methods: Pts with colon cancer undergoing adjuvant therapy with FOLFOX were randomized to IV CaMg (1g calcium gluconate plus 1g magnesium sulfate pre- and post-oxaliplatin) or placebo (PL) in a double-blinded manner. The primary endpoint was the percentage of pts with grade 2+ sNT at any time during or after oxaliplatin-based adjuvant therapy. NCI-CTC, an oxaliplatin-specific sNT scale (OSN) and patient-questionnaires were used to assess sNT. After 104 of planned 300 pts were enrolled, the study was closed in view of preliminary reports from another trial suggesting CaMg decreased treatment efficacy. Results: 102 pts (50 CaMg, 52 PL; 96 mFOLFOX6, 6 FOLFOX4) are available for analysis. Data of the intention-to-treat analysis are summarized in Table 1. CaMg delayed time-to- onset of G2+ sNT (log-rank: NCI-CTC p=0.091, OSN p=0.036). No difference in side-effects was noted between CaMg and PL. Conclusions: Despite early termination, our study demonstrates the activity of IV CaMg as neuroprotectant against oxaliplatin-induced sNT in adjuvant colon cancer. If further studies refute the notion that IV CaMg decreases the efficacy of FOLFOX, IV CaMg could be regarded as a standard component of oxaliplatin-based chemotherapy. G2+ sNT per treatment Toxicity scale CaMg Placebo P-Value NCI-CTC 22% 38.5% 0.07 OSN scale 28% 52% 0.01 Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration sanofi-aventis sanofi-aventis
A common polymorphism in the annexin V Kozak sequence (−1C&gt;T) increases translation efficiency and plasma levels of annexin V, and decreases the risk of myocardial infarction in young patients
Authors: Rocio González-Conejero, Javier Corral, Vanessa Roldán, Constantino Martı́nez, Francisco Marı́n, José Rivera, Juan A. Iniesta, Marı́a L. Lozano, Pascual Marco, Vicente Vicente
Journal: Blood (2002)
Telomerase Activity and Prognosis in Primary Breast Cancers
Authors: Lisa A. Carey, Nam W. Kim, Steven Goodman, Jeffrey Marks, Gregory Henderson, Christopher B. Umbricht, Jeffrey S. Dome, William Dooley, Stefan R. Amshey, Saraswati Sukumar
Journal: Journal of Clinical Oncology (1999)

PURPOSE: Recent studies associate telomerase activity with prognostic factors and survival. We compared quantitative telomerase activity in primary tumors with traditional prognostic factors and outcome in a group of invasive but nonmetastatic breast cancers. PATIENTS AND METHODS: Telomerase activity was measured in 203 invasive breast cancers by the quantitative telomeric repeat amplification protocol method. Telomerase expression was compared with 28S rRNA level, tumor content, and clinical variables, including outcome. For clinical correlations, telomerase activity was standardized by two methods: (1) a correction for cellularity using 28S rRNA levels, and (2) a correction for the histologically determined invasive proportion of the specimen. RESULTS: Telomerase activity was found in 82% of breast cancers with measurable 28S rRNA levels. Telomerase activity was associated with the proliferative index (P &lt; .01) of the tumor but not with any other prognostic variable. Neither uncorrected nor corrected telomerase activity was associated with relapse-free or overall survival in this study. CONCLUSION: Telomerase activity level was associated with the proliferative index of invasive breast cancers, but its measurement in samples from this group of nonmetastatic breast cancer patients did not predict survival.
Rapid Lung Function Improvement with Lebrikizumab in Patients with Uncontrolled Asthma
Authors: Jonathan Corren, Nicola A. Hanania, Phillip E. Korenblat, Julie K. Olssen, Nikhil Kamath, Sarah Gray, Nicolas Martin, Cecile T.J. Holweg, John G. Matthews, Susan L. Limb, Stephan Korom
Journal: Journal of Allergy and Clinical Immunology (2016)
A phase I clinical trial of a BDCA-1<sup>+</sup> blood dendritic cell preparation loaded with control and tumour-associated antigens, for immune therapy of metastatic refractory prostate cancer
Authors: R. Prue, T. Rosetti, S. Fitzpatrick, R. Wilkinson, K. Radford, P. Swindle, P. Mainwaring, D. N. Hart
Journal: Journal of Clinical Oncology (2005)

2599 Background: In vitro loaded dendritic cells (DC) are a promising new treatment for patients with prostate cancer. Blood DC (BDC) preparations may be an attractive alternative to the more commonly used monocyte-derived DC (MoDC) in terms of performance, logistics, cost and regulatory issues. In preclinical studies, we have shown that CD1c+ BDC can be isolated from prostate cancer patients with equivalent numerical and functional integrity compared to healthy donors, justifying their use as a platform for immunotherapy. Methods: We have validated a procedure for the isolation of CD1c+ BDC by positive immunoselection using the CliniMACS system that is suitable for clinical use. BDC isolated from HLA-A*0201+ patients are pulsed with PSA-3, PSMA-2, PAP-5, and influenza matrix protein (FMP) peptides. Patients receive 3 i.d. or i.v. injections at monthly intervals. Results: We are currently investigating cell yields, purity and functionality of this cell preparation. Approximately 0.12% of mononuclear cells obtained by leukapheresis are recovered with greater than 80% purity. Conclusions: Our data shows that sufficient BDCA-1+ BDC can be isolated using this system for a vaccine regimen. A Phase I trial to establish safety and efficacy in prostate cancer patients is currently underway. No significant financial relationships to disclose.
Mek Inhibitors are Effective Against Gastric Cancer Cell Lines with Oncogenic Mek1 Gene Mutations
Authors: Yosuke Togashi, Shunsuke Sogabe, Hiroaki Kato, Masato Terashima, Hidetoshi Hayashi, Kazuko Sakai, Yoshihiko Fujita, Shuta Tomida, Takushi Yasuda, Kazuto Nishio
Journal: Annals of Oncology (2014)
Computer-Assisted Collection and Analysis of Pathology Data
Authors: Charles H. Frith, Steven S. Herrick, Albert J. Konvicka
Journal: JNCI Journal of the National Cancer Institute (1977)

At the National Center for Toxicological Research, long-term experiments with mice requiring the collection, storage, retrieval, and analysis of an inordinate amount of data necessitated the development of an automated pathology information system. The system included automatic collection of mouse body and organ weights and hematologic findings; the use of mark-sensitive forms for the collection of gross and microscopic findings; and the use of computers for the storage, retrieval, and analysis of pathology data.
Monitoring during endoscopy
Authors: I. R Appadurai, R. J Delicta, P D. Carey
Journal: BMJ (1995)

Niuhuang Wan was found to contain 47 mg mercury and Zhusha Aushen 659 mg mercury (in the form of cinnabar).Arsenic and lead were also detected.When taken together as prescribed this would have resulted in a daily intake of 706 mg of cinnabar.We are concerned that the use of this amount of mercuric sulphide in long term treatment is potentially hazardous and could lead to mercury intoxication.Kew et al reported symptoms of mercury poisoning in a patient after daily exposure to 180-252 mg cinnabar for four weeks.2Cinnabar has been used for a long time in traditional medicines.The toxic effects of inorganic mercury are well recognised, but because of its insolubility it has been assumed that this compound would not be significantly absorbed from the gastrointestinal tract.However, a study by Yeon et al of the oral absorption of cinnabar in mice found a significant increase in mercury concentrations in the liver and kidney.Con- comitant use of cinnabar and drugs containing bromides, sulphates, sulphides, nitrates, and iodine may enhance its toxicity by increasing the gastrointestinal absorption.'We wish to bring the availability and use of these preparations to the attention of medical professionals and to emphasise the importance of obtaining full information on all the medications used by their patients.We are carrying out a traditional remedies surveillance project and would be interested in receiving reports of adverse reactions to herbal remedies and food supplements.
Do patients with recurrent ovarian cancer benefit from relative tumor reduction? Results from a prospective study
Authors: B. Gil, G. Oskay-Oezcelik, R. Richter, U. Neumann, P. Neuhaus, W. Lichtenegger, J. Sehouli
Journal: Journal of Clinical Oncology (2009)

e16541 Background: Primary cytoreduction is the cornerstone in the management of epithelial ovarian cancer (OC). However, the roles of salvage surgery and of tumor reduction are still discussed controversially. The present study was conducted to assess the impact of secondary tumor reduction surgery on progression-free survival and on overall survival. Methods: Between September 2000 and April 2006, 177 consecutive patients (pts) with a first relapse of OC underwent secondary tumor reduction surgery at our department. The achieved tumor reduction was categorized as 1/5 (20% tumor debulked), 2/5 (40%), 3/5 (60%), 4/5 (80%), or 5/5 (macroscopic tumor-free) and the maximal tumor diameter was also denoted (tumor free, &lt; 1cm, ≥ 1cm). Results: The median age was 56 years (95% CI: 23–83), median follow-up was 10.8 months (95% CI: 1–65). In 79 pts (44.6%) complete macroscopic tumor resection was achieved (median overall survival (OAS) 60.6 months, 21.3–99.8 and median progression-free survival (PFS) 14.9 months, 11.7–18, p &lt; 0.001). In 56 pts (31.6%) 4/5 of the tumor was removed (OAS 15.6 months, 10.3–20.8 and PFS 9 months, 7.2–10.7, p &lt; 0.001), in 13 (7.3%) 3/5 (OAS 21.7 months, no interval and PFS 12 months, 0.0–24.5, p &lt; 0.001) and in 7 (4%) each 2/5 tumor reduction (OAS was 14.2 months, 4.1–24.2 and PFS 11 months, 5.9–16, p &lt; 0.001) and if 1/5 tumor reduction was achieved OAS was 11.1 months, 2–20.1 and PFS 7 months, 2.5–11.4, p &lt; 0.001. Fifteen pts (8.5%) had a bulky unresected disease (OAS 4.7 months, 1.0–8.3 and PFS of 3.7 months, 0–7.6, p &lt; 0.001). From these 98 (55.4%) pts without complete macroscopic tumor resection, 46 were left with &lt;1cm tumor diameter (OAS 17.2 months, 13–21.4 and PFS 9 months, 7.4–10.6 p &lt; 0.001) and 52 with ≥1cm tumor diameter (OAS 8.7 months, 4.2–13.2 and PFS 7 months, 5.8–8.2 p &lt; 0.001). All in all, the median postoperative survival for pts with tumor residuals and any tumor reduction (4/5, 3/5, 2/5. and 1/5 tumor reduction) were better when compared to pts with no tumor reduction (24.8 months vs. 4.7, p &lt; 0.001). Conclusions: Our data demonstrate a significant benefit for salvage surgery if a macroscopic complete tumor resection can be achieved. We could not see any effect of relative tumor reduction on PFS or OAS. No significant financial relationships to disclose.